Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19.

J Infect Dis · 2022 · PMC9384575 · PMID 35895508

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

If an endpoint in the hierarchy did not reach statistical significance the subsequent data were reported descriptively.

also in 111,027 other papers

showed a trendno p-value reported

Treatment with CAS + IMD showed a trend in reduction in the proportions of patients who died or required mechanical ventilation, with improvement from days 1 to 29 in the high viral load (RRR, 35.0%; 95% CI, 6.6%–54.8%), seronegative (RRR, 47.0%; 95% CI, 17.7%–65.8%), and overall (RRR, 30.9%; 95% CI, 5.4%–49.5%) populations ( Table 2 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.